DHR · News · 20260807N
Revenue Performance and Mix
DANAHER CORP /DE/ · 2026-08-07 · Importance 31 · Surprise 32 · In source text
Danaher reported Q2 2026 revenue of $6.26 billion, up approximately 5.5% year over year and above analyst expectations. Core revenue growth and strong Life Sciences performance supported results, while Biotechnology revenue was weaker than expected. The mix shifted toward Diagnostics and Life Sciences as Biotechnology underperformed relative to the company’s other businesses.
Key facts
- Danaher reported $6.26 billion in revenue for the quarter and $1.94 adjusted EPS. source
- PensionDanmark Pensionsforsikringsaktieselskab increased its Danaher stake by 13.2% in Q2 to 134,442 shares valued at $25.6 million. source
- Benzinga reported Danaher had 5.54% revenue growth and a gross margin of 57.64% as of June 30, 2026. source
- Danaher shares increased 2.39% on Friday to close at $204.76, marking a third consecutive day of gains. source
- Institutional investors collectively own 79.05% of Danaher's stock. source
- Analysts' average price target for Danaher is $228.91. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | unclear | realized | — | Danaher reported $6.26 billion in revenue for the quarter and $1.94 adjusted EPS. |